C-peptide an adequate endpoint in type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 8, 2009, Pages 691-693

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

CLINICAL PRACTICE; CLINICAL RESEARCH; EDITORIAL; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTERVENTION STUDY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; QUALITY OF LIFE;

C-PEPTIDE; DIABETES MELLITUS, TYPE 1; ENDPOINT DETERMINATION; HUMANS;

EID: 73349090572     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1035     Document Type: Editorial

References (11)

1. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11(6): 541-548.
2. Ludvigsson J, Heding LG. C-peptide in children with juvenile diabetes. A preliminary report. Diabetologia 1976; 12(6): 627-630.
3. Ludvigsson J, Heding L, Liedén G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983; 286(6360): 176-178.
4. Stiller CR, Laupacis A, Dupre J, et al. Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl JMed 1983; 308(20): 1226-1227.
5. Nordwall M, Ludvigsson J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev 2008; 24: 472-479.
6. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
7. Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia 2007; 50(3): 503-509.
8. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
9. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3 {gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
10. Ludvigsson J, Faresjö M, HjorthM, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-1920.
11. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966-1971.